KRASG12C

First-in-class direct and covalent dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C

Daniel Gerlach, Associate Scientific Director, Computational Biology Oncology at Boehringer Ingelheim, shared a recent article on X:

“Discovery of BBO-8520, a first-in-class direct and covalent dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C, Cancer Discovery and American Association for Cancer Research.”

Title: Discovery of BBO-8520, a first-in-class direct and covalent dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C

Authors: Anna E. Maciag, James P. Stice, Bin Wang, Alok K. Sharma, Albert H. Chan, Ken Lin, Devansh Singh, Marcin Dyba, Yue Yang, Saman Setoodeh, Brian P. Smith, Jin Hyun Ju, Stevan Jeknic, Dana Rabara, Zuhui Zhang, Erik K. Larsen, Dominic Esposito, John-Paul Denson, Michela Ranieri, Mary Meynardie, Sadaf Mehdizadeh, Patrick A. Alexander, Maria Abreu Blanco, David M. Turner, Rui Xu, Felice C. Lightstone, Kwok-Kin Wong, Andrew G. Stephen, Keshi Wang, Dhirendra K. Simanshu, Kerstin W. Sinkevicius, Dwight V. Nissley, Eli Wallace, Frank McCormick and Pedro J. Beltran

KRASG12C

For more updates, follow OncoDaily.

Alok K. Sharma American Association for Cancer Research Anna E. Maciag Bin Wang Boehringer Ingelheim cancer Cancer Discovery Cancer research Daniel Gerlach Eli Wallace Frank McCormick James P. Stice KRASG12C OncoDaily Oncology Pedro J. Beltran